NASDAQ: VSTM · Life Sciences · 7 alerts · CIK 1526119
Share price
$7.70Close, Nov 16
Market cap
$970M
Shares outstanding
126.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Verastem, Inc. filings on SEC EDGAR ↗
Verastem President and CEO Dan Paterson Sells $12.5K of Stock
Dan Paterson, President and CEO, sold 1,299 shares of Verastem, Inc. at $9.60 a share, worth $12.5K in total on Nov 3, 2026. Shares held after the trade: 651,413 (-0.2%).
Verastem Oncology (VSTM) has published an updated corporate presentation for November 2026 detailing its pipeline of RAS/MAPK pathway-driven cancer therapies. The presentation highlights the commercialization strategy for AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer (LGSOC) and provides updates on its clinical trial programs, including RAMP 301 and collaborations with GenFleet Therapeutics.
Verastem reported Q3 2026 net product revenue of $24.0 million, a significant increase from $11.2 million in the prior year, driven by AVMAPKI FAKZYNJA CO-PACK sales. Despite a GAAP net loss of $74.7 million, the company strengthened its balance sheet with a $250 million follow-on offering in October, extending its cash runway into the first half of 2028.